Crispr Therapeutics AG (NASDAQ: CRSP) revenue
Crispr Therapeutics AG reported revenue of $3.5m for fiscal 2025, 90.6% less than in fiscal 2024 ($37.3m). Since fiscal 2016 its revenue has fallen by 32.0%, an average decline of 4.2% a year.
Crispr Therapeutics AG's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −99.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $3.5m | −90.6% | −$664.6m | −18,933.6% |
| 2024 | $37.3m | −89.9% | −$466.6m | −1,250.4% |
| 2023 | $371.2m | +30,885.5% | −$222.5m | −60.0% |
| 2022 | $1.2m | −99.9% | −$673.2m | −56,190.4% |
| 2021 | $915.0m | +127,154.9% | $373.5m | 40.8% |
| 2020 | $0.7m | −99.8% | −$354.4m | −49,295.5% |
| 2019 | $289.6m | +9,169.8% | $46.7m | 16.1% |
| 2018 | $3.1m | −92.4% | −$158.9m | −5,087.8% |
| 2017 | $41.0m | +693.9% | −$64.6m | −157.7% |
| 2016 | $5.2m | — | −$68.1m | −1,319.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Crispr Therapeutics AG revenue compared with its sector
By revenue for its latest fiscal year, Crispr Therapeutics AG ranks 385th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Crispr Therapeutics AG, −90.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 383rd | Ocugen | $4.4m | 8.8% |
| 384th | CG Oncology | $4.0m | 254.7% |
| 385th | Crispr Therapeutics AG | $3.5m | −90.6% |
| 386th | CAMP4 Therapeutics | $3.5m | 436.5% |
| 387th | Surrozen | $3.5m | −67.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Crispr Therapeutics AG
- How much revenue did Crispr Therapeutics AG make in fiscal 2025?
- Crispr Therapeutics AG reported revenue of $3.5m for fiscal 2025, compared with $37.3m in fiscal 2024.
- How much has the revenue of Crispr Therapeutics AG fallen?
- Between fiscal 2016 and fiscal 2025 it went from $5.2m to $3.5m: 32.0% less, an average decline of 4.2% a year.
- What was the best year for revenue at Crispr Therapeutics AG?
- Of its last 10 fiscal years, fiscal 2021, with $915.0m.
- Where does Crispr Therapeutics AG rank in its sector by revenue?
- It ranks 385th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Crispr Therapeutics AG come from?
- From the annual report (Form 10-K) that Crispr Therapeutics AG files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Crispr Therapeutics AG files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Crispr Therapeutics AG: the Crispr Therapeutics AG page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.